Get started
Author

Meaghan L. Khan

Observed names: M. L. Khan, Meaghan L Khan
OpenAlex ID: A5082159494
Carfilzomib: A Novel Second-Generation Proteasome Inhibitor
2011 · Meaghan L Khan, A Keith Stewart · Future Oncology · 90
Treatment With Bortezomib of a Patient Having Hyper IgG4 Disease
2010 · Meaghan L. Khan, Thomas V. Colby, et al. · Clinical Lymphoma Myeloma & Leukemia · 71
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
2011 · Meaghan L. Khan, Craig B. Reeder, et al. · British Journal of Haematology · 54
PDF
Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma
2014 · K. Martin Kortuem, Kaitlyn Zidich, et al. · Clinical Lymphoma Myeloma & Leukemia · 15
Immunotherapeutic and Oncolytic Viral Therapeutic Strategies in Pancreatic Cancer
2014 · Meaghan L Khan, Thorvardur R Halfdanarson, et al. · Future Oncology · 5
54-Year-Old Man With Severe Prostatism, Palatal Mass, and History of Pancreatitis
2012 · Kathryn B. Bollin, Meaghan L. Khan, et al. · Mayo Clinic Proceedings · 5
PDF
A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM).
2010 · M. L. Khan, C. B. Reeder, et al. · Journal of Clinical Oncology · 4
Immunotherapeutic and Oncolytic Viral Therapeutic Strategies in Pancreatic Cancer
2013 · Meaghan L Khan · Pancreatic Disorders and Therapy
Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma
2012 · Klaus Martin Kortuem, Steven R Schuster, et al. · Blood
Works count: 9
Citation count: 244
H-index: 5
I10-index: 4
Year
Topic
Type